In the third quarter, our revenue were $1 billion, driven by sales of our fully approved vaccines, Spikevax, mNEXSPIKE, ...

The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...

GSK said on Friday a panel ‍of the European Medicines Agency had backed the use of its ‌respiratory syncytial ‌virus (RSV) ...

Annual Meeting 2025 Highlights" report has been added to ResearchAndMarkets.com's offering. IDWeek is the joint annual meeting of the Infectious Diseases Society of America, the Society for Healthcare ...

Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...

Elders need to get shots this season to be protected against major viruses and other illnesses. There are many to choose from ...

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...